Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
An Open Label Extension Study to Evaluate Safety and Efficacy of Mepolizumab in Patients With Hypereosinophilic Syndromes
Sponsor: GlaxoSmithKline
Terminated
Study terminated by sponsor (29 Sep 2010). Subjects eligible to continue mepolizumab treatment were transferred into the compassionate use program (MHE104317)
Other terminated trials from GlaxoSmithKline
Other Hypereosinophilic Syndrome trials with similar outcome
Listed as NCT00097370, this PHASE3 trial focuses on Hypereosinophilic Syndrome and remains terminated or withdrawn. Sponsored by GlaxoSmithKline, it has been updated 11 times since 2004, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bad Bramstedt, Germany , Bethesda, United States , Bologna, Italy , Boston, United States , Brussels, Belgium , Cincinnati, United States , Denver, United States , Halifax, Canada , Hamilton, Canada , Hanover, Germany and 14 more locations